{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T17:50:36Z","timestamp":1790531436154,"version":"4.1.0"},"reference-count":97,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Porter\u2019s Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>GM1 gangliosidosis is a fatal neurodegenerative disease caused by a deficiency of lysosomal \u03b2-galactosidase. In its most severe form, GM1 gangliosidosis causes death by 4 years of age, and no effective treatments exist. Previous work has shown that injection of the brain parenchyma with an adeno-associated viral (AAV) vector provides pronounced therapeutic benefit in a feline GM1 model. To develop a less invasive treatment for the brain and increase systemic biodistribution, intravenous injection of AAV9 was evaluated.<\/jats:p>\n               <jats:p>AAV9 expressing feline \u03b2-galactosidase was intravenously administered at 1.5\u00d71013 vector genomes\/kg body weight to six GM1 cats at \u223c1 month of age. The animals were divided into two cohorts: (i) a long-term group, which was followed to humane end point; and (ii) a short-term group, which was analysed 16 weeks post-treatment. Clinical assessments included neurological exams, CSF and urine biomarkers, and 7 T MRI and magentic resonance spectroscopy (MRS). Post-mortem analysis included \u03b2-galactosidase and virus distribution, histological analysis and ganglioside content.<\/jats:p>\n               <jats:p>Untreated GM1 animals survived 8.0 \u00b1 0.6 months while intravenous treatment increased survival to an average of 3.5 years (n = 2) with substantial improvements in quality of life and neurological function. Neurological abnormalities, which in untreated animals progress to the inability to stand and debilitating neurological disease by 8 months of age, were mild in all treated animals. CSF biomarkers were normalized, indicating decreased CNS cell damage in the treated animals. Urinary glycosaminoglycans decreased to normal levels in the long-term cohort. MRI and MRS showed partial preservation of the brain in treated animals, which was supported by post-mortem histological evaluation. \u03b2-Galactosidase activity was increased throughout the CNS, reaching carrier levels in much of the cerebrum and normal levels in the cerebellum, spinal cord and CSF. Ganglioside accumulation was significantly reduced by treatment. Peripheral tissues such as heart, skeletal muscle, and sciatic nerve also had normal \u03b2-galactosidase activity in treated GM1 cats. GM1 histopathology was largely corrected with treatment. There was no evidence of tumorigenesis or toxicity.<\/jats:p>\n               <jats:p>Restoration of \u03b2-galactosidase activity in the CNS and peripheral organs by intravenous gene therapy led to profound increases in lifespan and quality of life in GM1 cats. These data support the promise of intravenous gene therapy as a safe, effective treatment for GM1 gangliosidosis.<\/jats:p>","DOI":"10.1093\/brain\/awab309","type":"journal-article","created":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T20:31:38Z","timestamp":1629232298000},"page":"655-669","source":"Crossref","is-referenced-by-count":24,"title":["Intravenous delivery of adeno-associated viral gene therapy in feline GM1 gangliosidosis"],"prefix":"10.1093","volume":"145","author":[{"given":"Amanda L","family":"Gross","sequence":"first","affiliation":[{"name":"Scott-Ritchey Research Center, College of Veterinary Medicine, Auburn University, Auburn, AL 36849 USA"},{"name":"Department of Anatomy, Physiology, and Pharmacology, College of Veterinary Medicine, Auburn University, AL 36849 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather L","family":"Gray-Edwards","sequence":"additional","affiliation":[{"name":"Scott-Ritchey Research Center, College of Veterinary Medicine, Auburn University, Auburn, AL 36849 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassie N","family":"Bebout","sequence":"additional","affiliation":[{"name":"Scott-Ritchey Research Center, College of Veterinary Medicine, Auburn University, Auburn, AL 36849 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan L","family":"Ta","sequence":"additional","affiliation":[{"name":"Biology Department, Boston College, Chestnut Hill, MA 02467 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayly","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Scott-Ritchey Research Center, College of Veterinary Medicine, Auburn University, Auburn, AL 36849 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon L","family":"Brunson","sequence":"additional","affiliation":[{"name":"Department of Anatomy, Physiology, and Pharmacology, College of Veterinary Medicine, Auburn University, AL 36849 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalajan R","family":"Lopez Mercado","sequence":"additional","affiliation":[{"name":"Scott-Ritchey Research Center, College of Veterinary Medicine, Auburn University, Auburn, AL 36849 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin E","family":"Osterhoudt","sequence":"additional","affiliation":[{"name":"Scott-Ritchey Research Center, College of Veterinary Medicine, Auburn University, Auburn, AL 36849 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5263-1360","authenticated-orcid":false,"given":"Ana Rita","family":"Batista","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Massachusetts Medical School, Worcester MA 01605 USA"},{"name":"Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester MA 01605 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy","family":"Maitland","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Massachusetts Medical School, Worcester MA 01605 USA"},{"name":"Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester MA 01605 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas N","family":"Seyfried","sequence":"additional","affiliation":[{"name":"Biology Department, Boston College, Chestnut Hill, MA 02467 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Sena-Esteves","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Massachusetts Medical School, Worcester MA 01605 USA"},{"name":"Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester MA 01605 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas R","family":"Martin","sequence":"additional","affiliation":[{"name":"Scott-Ritchey Research Center, College of Veterinary Medicine, Auburn University, Auburn, AL 36849 USA"},{"name":"Department of Anatomy, Physiology, and Pharmacology, College of Veterinary Medicine, Auburn University, AL 36849 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,8,19]]},"reference":[{"key":"2022041812232871500_awab309-B1","volume-title":"GeneReviews\u00ae. University of Washington, Seattle","author":"Regier","year":"2021"},{"issue":"5","key":"2022041812232871500_awab309-B2","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1586\/14737159.4.5.677","article-title":"Diagnosis of lysosomal storage disorders: Current techniques and future directions","volume":"4","author":"Meikle","year":"2004","journal-title":"Expert Rev Mol Diagn"},{"issue":"3831","key":"2022041812232871500_awab309-B3","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1126\/science.160.3831.1002","article-title":"Generalized gangliosidosis: Beta-galactosidase deficiency","volume":"160","author":"Okada","year":"1968","journal-title":"Science"},{"issue":"4","key":"2022041812232871500_awab309-B4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ymgme.2008.04.012","article-title":"GM1 gangliosidosis: Review of clinical, molecular, and therapeutic aspects","volume":"94","author":"Brunetti-Pierri","year":"2008","journal-title":"Mol Genet Metab"},{"issue":"1-2","key":"2022041812232871500_awab309-B5","first-page":"1","article-title":"Lysosomal storage diseases","volume":"2","author":"Ferreira","year":"2017","journal-title":"Transl Sci Rare Dis"},{"issue":"2","key":"2022041812232871500_awab309-B6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/hmg\/6.2.205","article-title":"Generalized CNS disease and massive GM1-ganglioside accumulation in mice defective in lysosomal acid beta-galactosidase","volume":"6","author":"Hahn","year":"1997","journal-title":"Hum Mol Genet"},{"issue":"6","key":"2022041812232871500_awab309-B7","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1023\/A:1018573518127","article-title":"Beta-galactosidase-deficient mouse as an animal model for GM1-gangliosidosis","volume":"14","author":"Matsuda","year":"1997","journal-title":"Glycoconj J"},{"issue":"1","key":"2022041812232871500_awab309-B8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0387-7604(96)00077-0","article-title":"Neurological manifestations of knockout mice with beta-galactosidase deficiency","volume":"19","author":"Matsuda","year":"1997","journal-title":"Brain Dev"},{"issue":"4011","key":"2022041812232871500_awab309-B9","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1126\/science.174.4011.838","article-title":"Neuronal GM1 gangliosidosis in a Siamese cat with beta-galactosidase deficiency","volume":"174","author":"Baker","year":"1971","journal-title":"Science"},{"issue":"1","key":"2022041812232871500_awab309-B10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005072-197301000-00001","article-title":"Feline GM 1 gangliosidosis: Biochemical and ultrastructural comparisons with the disease in man","volume":"32","author":"Farrell","year":"1973","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3","key":"2022041812232871500_awab309-B11","first-page":"649","article-title":"Animal model: Feline GM1 gangliosidosis","volume":"74","author":"Baker","year":"1974","journal-title":"Am J Pathol"},{"issue":"3","key":"2022041812232871500_awab309-B12","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/sj.ejhg.5201535","article-title":"Large animal models and gene therapy","volume":"14","author":"Casal","year":"2006","journal-title":"Eur J Hum Genet"},{"issue":"22","key":"2022041812232871500_awab309-B13","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/sj.gt.3302087","article-title":"Adeno-associated virus vector-mediated transduction in the cat brain","volume":"10","author":"Vite","year":"2003","journal-title":"Gene Ther"},{"issue":"10","key":"2022041812232871500_awab309-B14","doi-asserted-by":"crossref","first-page":"e13468","DOI":"10.1371\/journal.pone.0013468","article-title":"AAV-mediated gene delivery in adult GM1-gangliosidosis mice corrects lysosomal storage in CNS and improves survival","volume":"5","author":"Baek","year":"2010","journal-title":"PLoS ONE"},{"issue":"1","key":"2022041812232871500_awab309-B15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/sj.mt.6300004","article-title":"Complete correction of enzymatic deficiency and neurochemistry in the GM1-gangliosidosis mouse brain by neonatal adeno-associated virus-mediated gene delivery","volume":"15","author":"Broekman","year":"2007","journal-title":"Mol Ther"},{"issue":"231","key":"2022041812232871500_awab309-B16","doi-asserted-by":"crossref","first-page":"231ra48","DOI":"10.1126\/scitranslmed.3007733","article-title":"Sustained normalization of neurological disease after intracranial gene therapy in a feline model","volume":"6","author":"McCurdy","year":"2014","journal-title":"Sci Transl Med"},{"issue":"49","key":"2022041812232871500_awab309-B17","doi-asserted-by":"crossref","first-page":"17822","DOI":"10.1073\/pnas.0509062102","article-title":"Gene transfer of human acid sphingomyelinase corrects neuropathology and motor deficits in a mouse model of Niemann-Pick type A disease","volume":"102","author":"Dodge","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2022041812232871500_awab309-B18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1006\/mthe.1999.0005","article-title":"Long-term and significant correction of brain lesions in adult mucopolysaccharidosis type VII mice using recombinant AAV vectors","volume":"1","author":"Bosch","year":"2000","journal-title":"Mol Ther"},{"issue":"1","key":"2022041812232871500_awab309-B19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1006\/exnr.1999.7176","article-title":"Sustained production of beta-glucuronidase from localized sites after AAV vector gene transfer results in widespread distribution of enzyme and reversal of lysosomal storage lesions in a large volume of brain in mucopolysaccharidosis VII mice","volume":"160","author":"Skorupa","year":"1999","journal-title":"Exp Neurol"},{"issue":"9579","key":"2022041812232871500_awab309-B20","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/S0140-6736(07)60982-9","article-title":"Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: An open label, phase I trial","volume":"369","author":"Kaplitt","year":"2007","journal-title":"Lancet"},{"issue":"7","key":"2022041812232871500_awab309-B21","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/mt.2014.68","article-title":"Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10","volume":"22","author":"Yang","year":"2014","journal-title":"Mol Ther"},{"issue":"8","key":"2022041812232871500_awab309-B22","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/mt.2011.98","article-title":"Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system","volume":"19","author":"Zhang","year":"2011","journal-title":"Mol Ther"},{"issue":"1","key":"2022041812232871500_awab309-B23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat Biotechnol"},{"issue":"15","key":"2022041812232871500_awab309-B24","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1093\/hmg\/ddv168","article-title":"Systemic AAV9 gene transfer in adult GM1 gangliosidosis mice reduces lysosomal storage in CNS and extends lifespan","volume":"24","author":"Weismann","year":"2015","journal-title":"Hum Mol Genet"},{"issue":"7","key":"2022041812232871500_awab309-B25","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/mt.2009.71","article-title":"Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons","volume":"17","author":"Duque","year":"2009","journal-title":"Mol Ther"},{"issue":"5 Pt 1","key":"2022041812232871500_awab309-B26","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S1525-0016(03)00066-2","article-title":"Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for Canavan disease","volume":"7","author":"Matalon","year":"2003","journal-title":"Mol Ther"},{"issue":"2","key":"2022041812232871500_awab309-B27","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.neuroscience.2005.11.057","article-title":"Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain","volume":"138","author":"Broekman","year":"2006","journal-title":"Neuroscience"},{"issue":"4","key":"2022041812232871500_awab309-B28","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/mt.2015.231","article-title":"Widespread central nervous system gene transfer and silencing after systemic delivery of novel AAV-AS vector","volume":"24","author":"Choudhury","year":"2016","journal-title":"Mol Ther"},{"issue":"7","key":"2022041812232871500_awab309-B29","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat Methods"},{"issue":"5","key":"2022041812232871500_awab309-B30","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00401-005-1040-6","article-title":"Mutation of the GM2 activator protein in a feline model of GM2 gangliosidosis","volume":"110","author":"Martin","year":"2005","journal-title":"Acta Neuropathol"},{"issue":"3","key":"2022041812232871500_awab309-B31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11745-008-3268-0","article-title":"Comparative analysis of brain lipids in mice, cats, and humans with Sandhoff disease","volume":"44","author":"Baek","year":"2009","journal-title":"Lipids."},{"issue":"6","key":"2022041812232871500_awab309-B32","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.neuint.2007.12.001","article-title":"N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice","volume":"52","author":"Baek","year":"2008","journal-title":"Neurochem Int"},{"issue":"2","key":"2022041812232871500_awab309-B33","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1471-4159.1982.tb08662.x","article-title":"Differential cellular enrichment of gangliosides in the mouse cerebellum: Analysis using neurological mutants","volume":"38","author":"Seyfried","year":"1982","journal-title":"J Neurochem"},{"issue":"3","key":"2022041812232871500_awab309-B34","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1046\/j.1471-4159.2004.02381.x","article-title":"N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis","volume":"89","author":"Kasperzyk","year":"2004","journal-title":"J Neurochem"},{"issue":"9","key":"2022041812232871500_awab309-B35","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0022-2275(20)37906-2","article-title":"Analysis of brain lipids by high performance thin-layer chromatography and densitometry","volume":"24","author":"Macala","year":"1983","journal-title":"J Lipid Res."},{"issue":"1","key":"2022041812232871500_awab309-B36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1471-4159.1978.tb12428.x","article-title":"Cerebral, cerebellar, and brain stem gangliosides in mice susceptible to audiogenic seizures","volume":"31","author":"Seyfried","year":"1978","journal-title":"J Neurochem"},{"issue":"1","key":"2022041812232871500_awab309-B37","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0021-9258(18)64849-5","article-title":"A simple method for the isolation and purification of total lipides from animal tissues","volume":"226","author":"Folch","year":"1957","journal-title":"J Biol Chem"},{"issue":"4","key":"2022041812232871500_awab309-B38","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1194\/jlr.M400411-JLR200","article-title":"Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice","volume":"46","author":"Kasperzyk","year":"2005","journal-title":"J Lipid Res"},{"issue":"4","key":"2022041812232871500_awab309-B39","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.ymthe.2017.01.009","article-title":"Novel biomarkers of human GM1 gangliosidosis reflect the clinical efficacy of gene therapy in a feline model","volume":"25","author":"Gray-Edwards","year":"2017","journal-title":"Mol Ther"},{"key":"2022041812232871500_awab309-B40","doi-asserted-by":"crossref","first-page":"587680","DOI":"10.1155\/2013\/587680","article-title":"GAPDH pseudogenes and the quantification of feline genomic DNA equivalents","volume":"2013","author":"Helfer-Hungerbuehler","year":"2013","journal-title":"Mol Biol Int"},{"issue":"7","key":"2022041812232871500_awab309-B41","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/mt.2013.86","article-title":"Therapeutic response in feline Sandhoff disease despite immunity to intracranial gene therapy","volume":"21","author":"Bradbury","year":"2013","journal-title":"Mol Ther"},{"issue":"2","key":"2022041812232871500_awab309-B42","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ymgme.2008.02.004","article-title":"Molecular consequences of the pathogenic mutation in feline GM1 gangliosidosis","volume":"94","author":"Martin","year":"2008","journal-title":"Mol Genet Metab"},{"issue":"4","key":"2022041812232871500_awab309-B43","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/(SICI)1522-2594(199910)42:4<643::AID-MRM5>3.0.CO;2-N","article-title":"Developmental changes in choline- and ethanolamine-containing compounds measured with proton-decoupled (31)P MRS in in vivo human brain","volume":"42","author":"Bl\u00fcml","year":"1999","journal-title":"Magn Reson Med"},{"key":"2022041812232871500_awab309-B44","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/978-1-61737-992-5_9","article-title":"MR spectroscopy and spectroscopic imaging of the brain","volume":"711","author":"Zhu","year":"2011","journal-title":"Methods Mol Biol"},{"issue":"2","key":"2022041812232871500_awab309-B45","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/ar.1058","article-title":"Magnetic resonance spectroscopy of the human brain","volume":"265","author":"Ross","year":"2001","journal-title":"Anat Rec"},{"key":"2022041812232871500_awab309-B46","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3389\/fnmol.2016.00014","article-title":"A comprehensive review of the 1H-MRS metabolite spectrum in autism spectrum disorder","volume":"9","author":"Ford","year":"2016","journal-title":"Front Mol Neurosci"},{"issue":"1","key":"2022041812232871500_awab309-B47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11064-013-1199-5","article-title":"A guide to the metabolic pathways and function of metabolites observed in human brain 1H magnetic resonance spectra","volume":"39","author":"Rae","year":"2014","journal-title":"Neurochem Res"},{"issue":"3","key":"2022041812232871500_awab309-B48","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1471-4159.2006.03913.x","article-title":"The glutamate\/GABA-glutamine cycle: Aspects of transport, neurotransmitter homeostasis and ammonia transfer","volume":"98","author":"Bak","year":"2006","journal-title":"J Neurochem"},{"issue":"3","key":"2022041812232871500_awab309-B49","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum Gene Ther."},{"issue":"9","key":"2022041812232871500_awab309-B50","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","article-title":"Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: Results of phase 1 and 3 trials","volume":"126","author":"Maguire","year":"2019","journal-title":"Ophthalmology"},{"issue":"18","key":"2022041812232871500_awab309-B51","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"2022041812232871500_awab309-B52","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3233\/JHD-180302","article-title":"Selective neuronal uptake and distribution of AAVrh8, AAV9, and AAVrh10 in sheep after intra-striatal administration","volume":"7","author":"Mondo","year":"2018","journal-title":"J Huntingtons Dis"},{"issue":"4","key":"2022041812232871500_awab309-B53","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0896-6273(02)01054-1","article-title":"Drug and gene delivery to the brain: The vascular route","volume":"36","author":"Pardridge","year":"2002","journal-title":"Neuron"},{"issue":"3","key":"2022041812232871500_awab309-B54","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/ajmg.a.37468","article-title":"MRI\/MRS as a surrogate marker for clinical progression in GM1 gangliosidosis","volume":"170","author":"Regier","year":"2016","journal-title":"Am J Med Genet A."},{"issue":"5-6","key":"2022041812232871500_awab309-B55","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ejpn.2006.08.005","article-title":"Neuroimaging findings in infantile GM1 gangliosidosis","volume":"10","author":"Erol","year":"2006","journal-title":"Eur J Paediatr Neurol."},{"issue":"2","key":"2022041812232871500_awab309-B56","doi-asserted-by":"crossref","first-page":"175909141556990","DOI":"10.1177\/1759091415569908","article-title":"AAV-mediated gene delivery in a feline model of Sandhoff disease corrects lysosomal storage in the central nervous system","volume":"7","author":"Rockwell","year":"2015","journal-title":"ASN Neuro"},{"issue":"2","key":"2022041812232871500_awab309-B57","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/gt.2014.108","article-title":"Widespread correction of central nervous system disease after intracranial gene therapy in a feline model of Sandhoff disease","volume":"22","author":"McCurdy","year":"2015","journal-title":"Gene Ther"},{"issue":"6","key":"2022041812232871500_awab309-B58","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1089\/hum.2016.109","article-title":"Direct intracranial injection of AAVrh8 encoding monkey beta-N-acetylhexosaminidase causes neurotoxicity in the primate brain","volume":"28","author":"Golebiowski","year":"2017","journal-title":"Hum Gene Ther"},{"issue":"3","key":"2022041812232871500_awab309-B59","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ymthe.2020.01.006","article-title":"Adenovirus-antibody complexes contributed to lethal systemic inflammation in a gene therapy trial","volume":"28","author":"Somanathan","year":"2020","journal-title":"Mol Ther"},{"issue":"3","key":"2022041812232871500_awab309-B60","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.ymthe.2020.02.010","article-title":"Did dendritic cell activation, induced by adenovirus-antibody complexes, play a role in the death of Jesse Geisinger?","volume":"28","author":"Baker","year":"2020","journal-title":"Mol Ther"},{"issue":"17-18","key":"2022041812232871500_awab309-B61","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1089\/hum.2020.29133.bfs","article-title":"After third death, Audentes' AT132 remains on clinical hold","volume":"31","author":"Philippidis","year":"2020","journal-title":"Hum Gene Ther"},{"issue":"19","key":"2022041812232871500_awab309-B62","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139881","article-title":"Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme","volume":"5","author":"Elmore","year":"2020","journal-title":"JCI Insight"},{"issue":"7","key":"2022041812232871500_awab309-B63","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","article-title":"IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies","volume":"26","author":"Leborgne","year":"2020","journal-title":"Nat Med"},{"key":"2022041812232871500_awab309-B64","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.omtm.2020.01.004","article-title":"Successful transduction with AAV vectors after selective depletion of anti-AAV antibodies by immunoadsorption","volume":"16","author":"Orlowski","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"3","key":"2022041812232871500_awab309-B65","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1089\/humc.2015.068","article-title":"Evaluation of readministration of a recombinant adeno-associated virus vector expressing acid alpha-glucosidase in Pompe disease: Preclinical to clinical planning","volume":"26","author":"Corti","year":"2015","journal-title":"Hum Gene Ther Clin Dev"},{"issue":"2","key":"2022041812232871500_awab309-B66","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11011-008-9086-5","article-title":"Generation and characterization of recombinant feline beta-galactosidase for preclinical enzyme replacement therapy studies in GM1 gangliosidosis","volume":"23","author":"Samoylova","year":"2008","journal-title":"Metab Brain Dis"},{"issue":"9","key":"2022041812232871500_awab309-B67","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1089\/neu.2008.0738","article-title":"Validation of serum markers for blood-brain barrier disruption in traumatic brain injury","volume":"26","author":"Blyth","year":"2009","journal-title":"J Neurotrauma"},{"issue":"2","key":"2022041812232871500_awab309-B68","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/gt.2008.149","article-title":"Mechanisms of distribution of mouse beta-galactosidase in the adult GM1-gangliosidosis brain","volume":"16","author":"Broekman","year":"2009","journal-title":"Gene Ther"},{"issue":"11","key":"2022041812232871500_awab309-B69","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/mt.2011.157","article-title":"Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders","volume":"19","author":"Bevan","year":"2011","journal-title":"Mol Ther"},{"issue":"4","key":"2022041812232871500_awab309-B70","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1089\/hum.2011.200","article-title":"Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates","volume":"23","author":"Samaranch","year":"2012","journal-title":"Hum Gene Ther"},{"issue":"4","key":"2022041812232871500_awab309-B71","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/gt.2012.101","article-title":"Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates","volume":"20","author":"Gray","year":"2013","journal-title":"Gene Ther."},{"issue":"8","key":"2022041812232871500_awab309-B72","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1089\/hum.2019.012","article-title":"Safe and sustained expression of human iduronidase after intrathecal administration of adeno-associated virus serotype 9 in infant rhesus monkeys","volume":"30","author":"Hordeaux","year":"2019","journal-title":"Hum Gene Ther"},{"key":"2022041812232871500_awab309-B73","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/978-1-4939-9065-8_19","article-title":"Intrathecal delivery of AAV vectors in cynomolgus macaques for CNS gene therapy and gene expression analysis in microdissected motor neurons","volume":"1937","author":"Borel","year":"2019","journal-title":"Methods Mol Biol"},{"key":"2022041812232871500_awab309-B74","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.omtm.2020.04.001","article-title":"Intra-CSF AAV9 and AAVrh10 administration in nonhuman primates: Promising routes and vectors for which neurological diseases?","volume":"17","author":"Bey","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"21-22","key":"2022041812232871500_awab309-B75","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1089\/hum.2018.206","article-title":"A single injection of an optimized adeno-associated viral vector into cerebrospinal fluid corrects neurological disease in a murine model of GM1 gangliosidosis","volume":"31","author":"Hinderer","year":"2020","journal-title":"Hum Gene Ther"},{"issue":"5","key":"2022041812232871500_awab309-B76","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/gt.2014.16","article-title":"Intracisternal delivery of AAV9 results in oligodendrocyte and motor neuron transduction in the whole central nervous system of cats","volume":"21","author":"Bucher","year":"2014","journal-title":"Gene Ther"},{"issue":"7","key":"2022041812232871500_awab309-B77","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1089\/hum.2012.218","article-title":"scAAV9 intracisternal delivery results in efficient gene transfer to the central nervous system of a feline model of motor neuron disease","volume":"24","author":"Bucher","year":"2013","journal-title":"Hum Gene Ther"},{"issue":"10","key":"2022041812232871500_awab309-B78","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1016\/j.ymthe.2018.07.008","article-title":"Extensive transduction and enhanced spread of a modified AAV2 capsid in the non-human primate CNS","volume":"26","author":"Naidoo","year":"2018","journal-title":"Mol Ther"},{"issue":"5","key":"2022041812232871500_awab309-B79","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/gt.2016.6","article-title":"Intracerebroventricular delivery of self-complementary adeno-associated virus serotype 9 to the adult rat brain","volume":"23","author":"Donsante","year":"2016","journal-title":"Gene Ther"},{"key":"2022041812232871500_awab309-B80","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.omtm.2020.04.001","article-title":"Intra-CSF AAV9 and AAVrh10 administration in nonhuman primates: Promising routes and vectors for which neurological diseases?","volume":"17","author":"Bey","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"8","key":"2022041812232871500_awab309-B81","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1172\/JCI66778","article-title":"Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy","volume":"123","author":"Haurigot","year":"2013","journal-title":"J Clin Invest"},{"issue":"1","key":"2022041812232871500_awab309-B82","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/mt.2015.168","article-title":"Clinical improvement of alpha-mannosidosis cat following a single cisterna magna infusion of AAV1","volume":"24","author":"Yoon","year":"2016","journal-title":"Mol Ther"},{"issue":"12","key":"2022041812232871500_awab309-B83","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1038\/mt.2014.135","article-title":"Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I","volume":"22","author":"Hinderer","year":"2014","journal-title":"Mol Ther"},{"issue":"2","key":"2022041812232871500_awab309-B84","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nbt.3440","article-title":"Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain","volume":"34","author":"Deverman","year":"2016","journal-title":"Nat Biotechnol"},{"issue":"7","key":"2022041812232871500_awab309-B85","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/brain\/awaa161","article-title":"Global CNS correction in a large brain model of human alpha-mannosidosis by intravascular gene therapy","volume":"143","author":"Yoon","year":"2020","journal-title":"Brain"},{"issue":"11","key":"2022041812232871500_awab309-B86","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.ymthe.2019.07.017","article-title":"AAV-PHP.B administration results in a differential pattern of CNS biodistribution in non-human primates compared with mice","volume":"27","author":"Liguore","year":"2019","journal-title":"Mol Ther"},{"issue":"3","key":"2022041812232871500_awab309-B87","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ymthe.2018.01.018","article-title":"The neurotropic properties of AAV-PHP.B are limited to C57BL\/6J mice","volume":"26","author":"Hordeaux","year":"2018","journal-title":"Mol Ther."},{"key":"2022041812232871500_awab309-B88","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.neulet.2017.11.049","article-title":"Intravenous administration of the adeno-associated virus-PHP.B capsid fails to upregulate transduction efficiency in the marmoset brain","volume":"665","author":"Matsuzaki","year":"2018","journal-title":"Neuroscience Lett"},{"issue":"9","key":"2022041812232871500_awab309-B89","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1172\/JCI133953","article-title":"Krabbe disease successfully treated via monotherapy of intrathecal gene therapy","volume":"130","author":"Bradbury","year":"2020","journal-title":"J Clin Invest"},{"issue":"2","key":"2022041812232871500_awab309-B90","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/mt.2015.189","article-title":"Evaluation of AAV-mediated gene therapy for central nervous system disease in canine mucopolysaccharidosis VII","volume":"24","author":"Gurda","year":"2016","journal-title":"Mol Ther"},{"key":"2022041812232871500_awab309-B91","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.omtn.2016.12.006","article-title":"Inclusion of the woodchuck hepatitis virus posttranscriptional regulatory element enhances AAV2-driven transduction of mouse and human retina","volume":"6","author":"Patricio","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"issue":"15","key":"2022041812232871500_awab309-B92","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/sj.gt.3301221","article-title":"Influence of promoter and WHV post-transcriptional regulatory element on AAV-mediated transgene expression in the rat brain","volume":"7","author":"Paterna","year":"2000","journal-title":"Gene Ther"},{"issue":"14","key":"2022041812232871500_awab309-B93","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1089\/10430349950016942","article-title":"Enhanced expression of transgenes from adeno-associated virus vectors with the woodchuck hepatitis virus posttranscriptional regulatory element: Implications for gene therapy","volume":"10","author":"Loeb","year":"1999","journal-title":"Hum Gene Ther"},{"issue":"3","key":"2022041812232871500_awab309-B94","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/sj.mt.6300389","article-title":"Reversal of blindness in animal models of Leber congenital amaurosis using optimized AAV2-mediated gene transfer","volume":"16","author":"Bennicelli","year":"2008","journal-title":"Mol Ther"},{"issue":"1","key":"2022041812232871500_awab309-B95","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymthe.2004.10.004","article-title":"Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II","volume":"11","author":"Sun","year":"2005","journal-title":"Mol Ther"},{"issue":"3","key":"2022041812232871500_awab309-B96","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3233\/JND-190403","article-title":"AVXS-101 (Onasemnogene Abeparvovec) for SMA1: Comparative study with a prospective natural history cohort","volume":"6","author":"Al-Zaidy","year":"2019","journal-title":"J Neuromuscul Dis"},{"key":"2022041812232871500_awab309-B97","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.omtm.2019.12.001","article-title":"AAVrh10 vector corrects disease pathology in MPS IIIA mice and achieves widespread distribution of SGSH in large animal brains","volume":"17","author":"Hocquemiller","year":"2020","journal-title":"Mol Ther Methods Clin Dev"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awab309\/42574905\/awab309.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/145\/2\/655\/43390631\/awab309.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/145\/2\/655\/43390631\/awab309.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T12:29:09Z","timestamp":1650284949000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/145\/2\/655\/6355023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,19]]},"references-count":97,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,8,19]]},"published-print":{"date-parts":[[2022,4,18]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awab309","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,2,1]]},"published":{"date-parts":[[2021,8,19]]}}}